Brendan Smith
Stock Analyst at TD Cowen
(4.89)
# 372
Out of 4,683 analysts
286
Total ratings
57.8%
Success rate
36.1%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OABI OmniAb | Maintained: Buy | $3 → $5 | $4.81 | +3.95% | 12 | Aug 17, 2026 | |
| MXCT MaxCyte | Maintained: Buy | n/a | $1.31 | - | 12 | Aug 13, 2026 | |
| CDXS Codexis | Maintained: Hold | $2 | $1.65 | +21.21% | 11 | Aug 11, 2026 | |
| MASS 908 Devices | Maintained: Buy | n/a | $10.37 | - | 11 | Aug 11, 2026 | |
| ABSI Absci | Maintained: Buy | n/a | $9.22 | - | 10 | Aug 11, 2026 | |
| PASG Passage Bio | Maintained: Hold | n/a | $4.50 | - | 11 | Aug 10, 2026 | |
| HALO Halozyme Therapeutics | Rated: Buy | $96 → $105 | $107.06 | -1.92% | 24 | Aug 7, 2026 | |
| BLFS BioLife Solutions | Maintained: Hold | $31 | $37.00 | -16.22% | 13 | Aug 7, 2026 | |
| DNA Ginkgo Bioworks Holdings | Downgraded: Hold | $12 → $9 | $7.23 | +24.48% | 14 | Aug 7, 2026 | |
| AZTA Azenta | Maintained: Hold | $20 → $33 | $33.57 | -1.70% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $19.47 | +2.72% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.24 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.49 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $7.22 | -3.05% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $4.57 | +9.41% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $8.22 | +9.49% | 10 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $89 → $115 | $150.06 | -23.36% | 18 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $180.30 | +10.93% | 11 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $410 | $349.92 | +17.17% | 7 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 → $2 | $1.95 | +2.56% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2 | $29.05 | -93.12% | 1 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $18.41 | -13.09% | 5 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.67 | - | 7 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $89.12 | n/a | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $24.57 | n/a | 11 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 → $9 | $9.21 | n/a | 6 | Nov 12, 2024 |
OmniAb
Aug 17, 2026
Maintained: Buy
Price Target: $3 → $5
Current: $4.81
Upside: +3.95%
MaxCyte
Aug 13, 2026
Maintained: Buy
Price Target: n/a
Current: $1.31
Upside: -
Codexis
Aug 11, 2026
Maintained: Hold
Price Target: $2
Current: $1.65
Upside: +21.21%
908 Devices
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $10.37
Upside: -
Absci
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $9.22
Upside: -
Passage Bio
Aug 10, 2026
Maintained: Hold
Price Target: n/a
Current: $4.50
Upside: -
Halozyme Therapeutics
Aug 7, 2026
Rated: Buy
Price Target: $96 → $105
Current: $107.06
Upside: -1.92%
BioLife Solutions
Aug 7, 2026
Maintained: Hold
Price Target: $31
Current: $37.00
Upside: -16.22%
Ginkgo Bioworks Holdings
Aug 7, 2026
Downgraded: Hold
Price Target: $12 → $9
Current: $7.23
Upside: +24.48%
Azenta
Aug 5, 2026
Maintained: Hold
Price Target: $20 → $33
Current: $33.57
Upside: -1.70%
Aug 5, 2026
Maintained: Buy
Price Target: $20
Current: $19.47
Upside: +2.72%
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $12.24
Upside: -
Aug 5, 2026
Maintained: Hold
Price Target: n/a
Current: $3.49
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $7
Current: $7.22
Upside: -3.05%
Aug 5, 2026
Maintained: Hold
Price Target: $5
Current: $4.57
Upside: +9.41%
Aug 4, 2026
Maintained: Buy
Price Target: $9
Current: $8.22
Upside: +9.49%
Aug 3, 2026
Rated: Buy
Price Target: $89 → $115
Current: $150.06
Upside: -23.36%
Jul 28, 2026
Maintained: Buy
Price Target: $200
Current: $180.30
Upside: +10.93%
Jul 23, 2026
Rated: Buy
Price Target: $410
Current: $349.92
Upside: +17.17%
Jul 15, 2026
Downgraded: Hold
Price Target: $4 → $2
Current: $1.95
Upside: +2.56%
Jul 14, 2026
Downgraded: Hold
Price Target: $2
Current: $29.05
Upside: -93.12%
Jul 9, 2026
Maintained: Hold
Price Target: $16
Current: $18.41
Upside: -13.09%
May 27, 2026
Maintained: Buy
Price Target: n/a
Current: $1.67
Upside: -
May 13, 2025
Maintained: Buy
Price Target: n/a
Current: $89.12
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: n/a
Current: $24.57
Upside: n/a
Nov 12, 2024
Maintained: Hold
Price Target: $14 → $9
Current: $9.21
Upside: n/a